semaglutide news october 26 2025 GLP-1 trends 2025: real-world data, patient outcomes & future therapies Semaglutide as a MASH Treatment:

"One thing thats true, universally, many of them are still not completely satisfied with the decision theyve made," said Shao

A study involving patients with T2DM by Zander et al

Zoe Deol and Dr

These hemodynamic interactions are not reflected in current prescribing information for tirzepatide, not because they have been evaluated and found absent, but because patients with hEDS and POTS were not systematically enrolled in the pivotal SURMOUNT trials, which excluded individuals with significant cardiovascular, renal, and neurological comorbidities

PPARalpha and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia

They enhance insulin secretion when blood glucose levels are elevated, suppress glucagon release (which normally raises blood sugar), and slow gastric emptying